News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Resolv ER may remedy leading causes of blindness in adults
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Subscribe To Our Newsletter & Stay Updated
